Imperative Care has secured $85m in a Series C financing to advance the launch of its portfolio of advanced neurovascular devices for treating ischemic and hemorrhagic strokes.

The funding round was led by new investors Ally Bridge Group and Bain Capital Life Sciences, and the existing investors including Ascension Ventures, Delos Capital, Rock Springs Capital, 3H Health Investment, and Incept also participated in the funding round.

As part of the investment, Ally Bridge founder Frank Yu and Bain Capital managing director Andrew Hack will be appointed as Imperative Care Board of Directors.

Imperative Care chairman and CEO Fred Khosravi said: “We are thrilled to have Ally Bridge and Bain Capital leading this round of financing at this important stage in our company’s growth. We look forward to Frank and Andrew’s support and guidance as we continue to propel forward Imperative Care’s unique mission. This is an exciting time for our company.

“We are poised to launch the industry’s first Large Distal Platform (LDP) access technology and our unparalleled ZOOM Aspiration System. In addition, we continue to develop a pipeline of innovations in the continuum of stroke-care, with significant investment and emphasis on clinical evidence.”

Imperative Care is dedicated to improving stroke treatment

According to The New England Journal of Medicine, approximately 25% among both men and women above the age of 25 years are estimated to be at risk of stroke globally.

Imperative Care said that it has secured the US Food and Drug Administration (FDA) 510(k) approval for its family of access catheters, intended for delivering smooth, consistent navigation into blood vessels of the brain.

It has also received the FDA approval for its ZOOM Aspiration System family of products, designed for removing blood clots during ischemic stroke.

Imperative Care was established in 2016, in Campbell, California, by Nick Hopkins and Fred Khosravi. The company develops a range of advanced solutions encompassing the unmet needs in stroke care.

The company claimed that it is devoted to improving stroke treatment through advancing medical technology and enabling healthcare providers to develop best practices and enhance the standard of care for stroke patients.